Dr Reddys Laboratories Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Indicators

Technical Trend Overview and Price Movement

The stock closed at ₹1,255.45 on 5 Jan 2026, marginally up by 0.15% from the previous close of ₹1,253.60. The intraday range was between ₹1,236.00 and ₹1,257.65, indicating moderate volatility. Despite this modest gain, the technical trend has shifted from mildly bearish to mildly bullish, signalling a potential change in investor sentiment.

Dr Reddys Laboratories is currently trading below its 52-week high of ₹1,404.60 but comfortably above its 52-week low of ₹1,025.90. This positioning suggests the stock is in a consolidation phase, with technical indicators providing mixed signals on the near-term direction.

MACD Signals: Divergent Weekly and Monthly Perspectives

The Moving Average Convergence Divergence (MACD) indicator presents a bifurcated view. On the weekly chart, the MACD is bullish, indicating upward momentum in the short term. This suggests that the recent price action is gaining strength, potentially attracting buyers. Conversely, the monthly MACD remains mildly bearish, reflecting a longer-term caution among investors. This divergence implies that while short-term momentum is improving, the broader trend still warrants careful monitoring.

RSI and Bollinger Bands: Neutral to Bearish Signals

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, hovering in neutral territory. This lack of momentum extremes suggests the stock is neither overbought nor oversold, leaving room for directional movement based on upcoming catalysts.

Bollinger Bands on the weekly chart indicate a bearish stance, with the price nearing the lower band, signalling potential downward pressure or increased volatility. However, the monthly Bollinger Bands show a sideways trend, reinforcing the notion of consolidation over the longer term.

Moving Averages and KST: Mixed Momentum Indicators

Daily moving averages have turned bullish, supporting the recent positive price momentum. This short-term bullishness is a key factor in the overall mild bullish trend shift. However, the Know Sure Thing (KST) oscillator presents a bearish signal on the weekly chart and a mildly bearish stance on the monthly chart, indicating that momentum may be weakening beyond the immediate term.

Volume and Dow Theory Analysis

On-Balance Volume (OBV) is mildly bearish on the weekly timeframe, suggesting that volume trends are not strongly supporting the recent price gains. The monthly OBV shows no clear trend, indicating a lack of conviction among traders over the longer horizon.

Dow Theory assessments reveal a mildly bearish weekly outlook but a mildly bullish monthly perspective. This mixed reading aligns with the broader technical picture of short-term optimism tempered by longer-term caution.

Comparative Returns and Market Context

Dr Reddys Laboratories’ recent returns have lagged behind the broader Sensex benchmark. Over the past week, the stock declined by 1.07% compared to the Sensex’s 0.85% gain. The one-month and year-to-date returns also show underperformance, with the stock down 1.63% and 1.23% respectively, while the Sensex rose 0.73% and 0.64% over the same periods.

Over a longer horizon, the stock’s 1-year return is -8.61%, contrasting with the Sensex’s 7.28% gain. However, the 3-year return of 48.13% outpaces the Sensex’s 40.21%, indicating strong medium-term growth. The 5-year and 10-year returns of 19.78% and 102.11% lag behind the Sensex’s 79.16% and 227.83%, reflecting mixed long-term performance.

Mojo Score Upgrade and Market Capitalisation Grade

MarketsMOJO has upgraded Dr Reddys Laboratories’ Mojo Grade from Sell to Hold as of 1 Dec 2025, reflecting improved technical and fundamental outlooks. The current Mojo Score stands at 67.0, signalling a neutral stance with potential for upside. The company holds a Market Cap Grade of 1, indicating a large-cap status but with limited recent market cap momentum.

Investment Implications and Outlook

The shift to a mildly bullish technical trend suggests that Dr Reddys Laboratories may be entering a phase of cautious optimism. Short-term indicators such as the daily moving averages and weekly MACD support this view, while longer-term signals remain mixed or mildly bearish. Investors should weigh these factors carefully, considering the stock’s recent underperformance relative to the Sensex and the pharmaceutical sector’s broader dynamics.

Given the neutral RSI and sideways Bollinger Bands on monthly charts, the stock appears poised for a potential breakout or breakdown depending on upcoming market catalysts, including sectoral developments and company-specific news.

Summary

Dr Reddys Laboratories Ltd’s technical landscape is evolving, with a mild bullish shift signalling renewed interest among traders and investors. While short-term momentum indicators such as the daily moving averages and weekly MACD support this positive tilt, longer-term indicators including monthly MACD, KST, and OBV counsel caution. The stock’s recent underperformance relative to the Sensex adds to the complexity of the outlook.

Investors should monitor key technical levels and broader market conditions closely. The current Mojo Grade of Hold reflects this balanced view, suggesting that while the stock is not a strong buy at present, it remains a viable candidate for selective accumulation within a diversified portfolio.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today